PharmStar Pharmaceuticals, Inc. Appoints Howard Phykitt as Chairman and CEO

ROCKY MOUNT, NC--(Marketwire - March 18, 2011) - PharmStar Pharmaceuticals, Inc. (formerly known as Big Star Media Group) (PINKSHEETS: BMGI), which is focused on the manufacturing and marketing of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, announced today the appointment of Howard Phykitt as Chairman of the Board of Directors and Chief Executive Officer of the Company.

Having spent the past 17 years researching, testing, patenting and developing Aquaprin, Mr. Phykitt is now ready to bring his most important work to the $30 billion pain management industry. In the 1970s, Mr. Phykitt developed a unique granulation and coating technology that is used today by Eli Lily, Glaxo Smithkline and others in the manufacturing of a litany of pharmaceutical products. In 1984, Mr. Phykitt founded Granutec, Inc., where he developed fluid bed micro-encapsulation for use in the pharmaceutical and agriculture industries. By 1988, Granutec grew to $6 million in sales, and rose to over $60 million in sales to companies such as Walmart, Eckerd, Perry Drug, and Rite Aid by 1993.

In connection with the Company's new management team and business strategy focused on commercializing Aquaprin, PharmStar Pharmaceuticals, Inc. has launched a corporate website at www.pharmstarinc.com.

About PharmStar Pharmaceuticals, Inc.
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin, and is now ready for commercialization. Aquaprin™'s unique, patent-pending formula is designed to dissolve nearly instantly in just 1.5 ounces of water. This enables the product to be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.

Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.


Contact:
PharmStar Pharmaceuticals, Inc.
919-794-7000
Email Contact
www.pharmstarinc.com

Investor Contact:
Email Contact

Back to news